Companies

NectomeWinter 2018Active

South San Francisco · CA, USA · founded 2017 · https://nectome.com/

Diligence memoA one-page analyst read on Nectome — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 5%
Sector rank · raised
Latest stage · inferred

Nectome: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Building a way to preserve long-term memories.

Nectome is a neuroscience startup that aims to preserve the brain and keep all its memories intact. The company is building the next generation of tools to preserve the connectome. The connectome is all the connections called synapses between neurons in the brain. Researchers from the company is now learning to manipulate individual memories, building advanced brain prosthetics, and reverse-engineering the brain.

Neurotechnology
Find Nectome online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$1.3M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$14.6M

Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

Nectome is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Neuralink Corp.
Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.
BiotechnologyGrowth/Late$6.4B71%
Brain Tunnelgenix Technologies CorpBiotechnologySeries B$86.5M70%
Neuroscience Innovations, Inc.Other TechnologyPre-Seed$1.6M69%
Brain CorpOther TechnologySeries B$272.3M69%
Synapticure, Inc.
We deliver personalized medicine for neurodegenerative patients
BiotechSeries C$332.9M69%
Neuromotion Inc.Other TechnologySeries A$194.2M69%
Neuralmagic, Inc.Other TechnologySeries B$567.9M69%
NeuroBionics Inc.Other TechnologySeries A$13.3M69%
Frequently asked
What does Nectome do and where is it based?
Nectome is a private company, based in South San Francisco, CA, USA. Building a way to preserve long-term memories.
Explore related

See where Nectome sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nectome, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.